Reported side effects are typically mild: Morning grogginess: Uncommon, usually associated with initial dosing or timing adjustments Vivid dreams: Some patients report more vivid dreams, which may reflect enhanced REM sleep Headache: Occasionally reported, usually mild and transient Injection site reactions: Minor redness or discomfort at the injection site DSIP has not demonstrated significant interactions with common medications in published studies
DISSECTION P938 - ESOC25-2421 CADASIL Argentine Registry (CADASILar): Establishing a Harmonized Clinical Protocol preliminary data Julieta Rosales 1 , Carolina Ardohain 2 , Juan Lopez 3 , Fabio Gonzalez 4 , Julian Alonso 5 , Valentin Selvaggi 6 , Diana Cristalli 7 , Ismael Calandri 2 1 Clinica Sagrada Familia-ENERI, Buenos Aires, Argentina, 2 FLENI, Buenos Aires, Argentina, 3 Sanatorio Los Arcos, Buenos Aires, Argentina, 4 Hospital Italiano de Bs As, Buenos Aires, Argentina, 5 Hospital Posadas, Buenos Aires, Argentina, 6 Hospital Ramos Meja, Buenos Aires, Argentina, 7 Centro Jesi, Buenos Aires, Argentina Background and Aims: CADASIL, a leading monogenic small vessel disease caused by NOTCH3 mutations, manifests with migraines, strokes, and cognitive decline
Three main body areas are medically approved for this injection: the abdomen, the thigh, and the upper arm
5, column 5, B5-G5)
Do all tirzepatide vials require mixing
"Elevated serum homocysteine, low serum vitamin B12, folate, and age-related macular degeneration: the Blue Mountains Eye Study"
